Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

The U.S.FDA Granted CellTrans Inc., Approval of its Product Lantidra for the Treatment of Type 1 Diabetes

June 30, 2023 0

CellTrans Inc FDA Approval for Lantidra for Type 1 Diabetes The U.S. Food and Drug Administration …

The U.S. FDA Approved BioMarin Pharmaceutical’s ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A

June 30, 2023 0

BioMarin Pharmaceutical US FDA Approved ROCTAVIAN BioMarin Pharmaceutical (BMRN) announced that the U.S. FDA approved ROCTAVIAN …

Bayer & BlueRock Therapeutics: A First Neuronal Stem Cell Therapy to Show Positive Results in Phase I Clinical Study for Parkinson’s Disease

June 29, 2023 0

Bayer and BlueRock Therapeutics Berlin, Germany and Cambridge, M.A., U.S.A., June 28, 2023 – Bayer AG (BAYRY) …

Prohost Letter #455

June 28, 2023 0

Prohost Letter #455 Introduction Our Prohost Letter disappeared for six months. Several reasons dictated our decision …

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in Netherlands to Start Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca Imfinzi for Treatment of Pancreatic Cancer

June 27, 2023 0

AIM ImmunoTech Announcement AIM ImmunoTech (AIM) - an immuno-pharma company focused on the research and development …

Celmatix Inc: Revolutionizing Fertility Treatments

June 27, 2023 0

Celmatix Inc. Celmatix Inc., announced the identification of promising early leads in its latest drug program, …

Arbutus Biopharma Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial That Includes a PD-1 Monoclonal Antibody Nivolumab

June 21, 2023 0

Arbutus Biopharma Announcement Today, June 21, 2023, Arbutus Biopharma (ABUS) announced that the first patient has …

Vera Therapeutics Announces Positive Week 36 Safety and Efficacy Results in Phase 2b Clinical Trial of Atacicept in IgA Nephropathy

June 20, 2023 0

Vera Therapeutics Vera Therapeutics (VERA) announced that Phase 2b ORIGIN clinical trial of atacicept for IgA …

At 2:30 PM Today the Chairman of the Federal Reserve will Reveal the Decision About Interest Rates. See Also: Good News from Gilead

June 14, 2023 0

Today at 2.30... Today at 2.30, the Federal Reserve Chairman Jerome Powell will speak to the …

Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

June 1, 2023 0

UT Southwestern Medical Center and RenovoRx RenovoRx Inc (RNXT) announced that the University of Texas (UT) …

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

May 30, 2023 0

Amylyx Pharmaceuticals Amylyx Pharmaceuticals (AMLX) announced an update on the ongoing review of its Marketing Authorization …

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

May 26, 2023 0

Inside the Revolution In the Treatments of Untreatable Diseases We are now living a great revolution …

Our Eyes Are on Reata Pharmaceuticals Today

May 25, 2023 0

Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease …

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis

May 19, 2023 0

Intercept Pharmaceuticals Intercept Pharmaceuticals Inc (ICPT) is a biopharmaceutical company focused on the development and commercialization …

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

May 1, 2023 0

May 01, 2023 (GLOBE NEWSWIRE) –Today, Intellia Therapeutics (NTLA) released its 2023 Corporate Responsibility report. The …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

The U.S.FDA Granted CellTrans Inc., Approval of its Product Lantidra for the Treatment of Type 1 Diabetes

The U.S. FDA Approved BioMarin Pharmaceutical’s ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A

Bayer & BlueRock Therapeutics: A First Neuronal Stem Cell Therapy to Show Positive Results in Phase I Clinical Study for Parkinson’s Disease

Prohost Letter #455

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in Netherlands to Start Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca Imfinzi for Treatment of Pancreatic Cancer

Celmatix Inc: Revolutionizing Fertility Treatments

Arbutus Biopharma Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial That Includes a PD-1 Monoclonal Antibody Nivolumab

Vera Therapeutics Announces Positive Week 36 Safety and Efficacy Results in Phase 2b Clinical Trial of Atacicept in IgA Nephropathy

At 2:30 PM Today the Chairman of the Federal Reserve will Reveal the Decision About Interest Rates. See Also: Good News from Gilead

Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

Our Eyes Are on Reata Pharmaceuticals Today

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis

Bio-Techne ExoDx Prostate Test is More Accurate in High- and Low-Risk Patients Compared to Standard of Care

Celldex Therapeutics Presented Positive Preclinical Data from its TSLP/SCF Bispecific Antibody Program CDX-622 at AAI

Longeveron has Encouraging Trial Results for Hypoplastic Left Heart Syndrome

Why CureVac Stock Traded Up in a Bad Day Market

CHMP Adopts Positive Opinion for Full Marketing Authorization of Gilead’s Hepcludex® Treatment of HDV

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities